Relative Publications

T Tim Bognàr 1, J S Jurjen Kingma 2 3, E H Erin Smeijsters 2, K C M Kim van der Elst 2, C T M Klaartje de Kanter 4, C A Caroline Lindemans 5 6, A C G Toine Egberts 2 7, I H Imke Bartelink # 8 9, A Arief Lalmohamed # 2 7 Affiliations Expand PMID: 37002411 DOI: 10.1038/s41409-023-01971-z Abstract Busulfan exposure has previously been linked to clinical outcomes, hence the need for therapeutic drug monitoring (TDM). Study objective was to evaluate the effect of day 1 TDM-guide

Abstract Background: Therapeutic drug monitoring (TDM) of busulfan is recommended for hematopoietic stem cell transplant recipients. Timely reporting of these TDM results is essential given the short administration period and the planned dose adjustments on day 2. The authors evaluated the performance of a new nanoparticle-based competitive immunoassay on two routine clinical chemistry analyzers and compared its performance to that of an in-house high-resolution mass spectrom

Jeanne Palmer 1, Jeannine S McCune 2, Miguel-Angel Perales 3, David Marks 4, Joseph Bubalo 5, Mohamad Mohty 6, John R Wingard 7, Angelo Paci 8, Moustapha Hassan 9, Christopher Bredeson 10, Joseph Pidala 11, Nina Shah 12, Paul Shaughnessy 13, Navneet Majhail 14, Jeff Schriber 15, Bipin N Savani 16, Paul A Carpenter 17 Affiliations Expand PMID: 27481448 DOI: 10.1016/j.bbmt.2016.07.013 Free article Abstract The Practice Guidelines Committee of the American Society of Blood or Ma